Linagliptin/Metformin Stada

Linagliptin, the active ingredient in Linagliptin/Metformin Stada, is a DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adult patients when diet and exercise alone are insufficient and is indicated for patients with inadequate glycaemic control.

GNH USA supplies Linagliptin/Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, addressing hyperglycaemia through complementary mechanisms. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when used together with diet and exercise. - Inadequate control on metformin alone: adds DPP‑4 inhibition to achieve target HbA1c levels in patients not reaching goals. - Combination with other oral antidiabetics: provides additive glucose‑lowering effect for patients requiring multi‑drug regimens. - Adjunct to insulin therapy: enhances glycaemic control when added to basal insulin in advanced disease.

The most frequently reported adverse reactions with Linagliptin/Metformin involve the gastrointestinal system and metabolic disturbances, while rare but serious events have also been documented.

Common Side Effects: - Nausea: mild to moderate nausea, especially at treatment start. - Diarrhoea: loose stools that often improve over time. - Headache: transient headache episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis linked to metformin. - Pancreatitis: inflammation of the pancreas with severe abdominal pain. - Severe hypersensitivity: rash, angioedema, or anaphylaxis.

When prescribing Linagliptin/Metformin, clinicians should consider several safety precautions to minimise risk. - Renal function assessment: evaluate eGFR before initiation and monitor periodically. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in individuals with severe renal or hepatic dysfunction. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh potential risks. - Drug interaction review: assess concomitant medications for potential additive hypoglycaemia or renal effects. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Linagliptin/Metformin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: may cause severe hypoglycaemia. - Metformin in severe renal impairment: increases risk of lactic acidosis. - Iodinated contrast agents: can precipitate acute kidney injury when combined with metformin.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - Cimetidine: can raise linagliptin plasma concentrations. - Beta‑blockers: may mask hypoglycaemia symptoms.